WHO Pharmaceuticals Newsletter 1998, No. 09&10
(1998; 23 pages)
Índice de contenido
Abrir esta carpeta y ver su contenidoRegulatory decisions
Cerrar esta carpetaDrug surveillance
Ver el documentoAlbumin and plasma protein fraction - safety concerns: USA
Ver el documentoAlendronic acid - reminder: oesophageal reactions: UK
Ver el documentoDrug-induced amnesia - review: Australia
Ver el documentoIsotretinoin - depression: Australia
Ver el documentoIsotretinoin - adverse reaction profile: UK
Ver el documentoLeukotriene antagonists: montelukast & zafirlukast - safe use: UK
Ver el documentoLevonorgestrel - use for emergency contraception: WHO/HRP
Ver el documentoSelective serotonin reuptake inhibitors (SSRIs) - haemorrhage: Australia
Ver el documentoSildenafil (Viagra) - summary of reports of death: update: USA
Ver el documentoTryptophan, 5HTP and eosinophilia-myalgia syndrome - impurities confirmed: USA
Abrir esta carpeta y ver su contenidoNew developments
Abrir esta carpeta y ver su contenidoMedical devices
Abrir esta carpeta y ver su contenidoGeneral information
Abrir esta carpeta y ver su contenidoMedication errors
Abrir esta carpeta y ver su contenidoVeterinary medicine
 

Drug-induced amnesia - review: Australia

Australia. Amnesia or memory impairment in association with drug therapy is a rare occurrence. The Adverse Drug Reactions Advisory Committee has received only 210 reports of this adverse reaction in the past 10 years.

There are some drugs such as the benzodiazepines which are established as a cause of amnesia and would not normally be the subject of a report because the association is well known. The drugs most commonly reported to the ADRAC in the past 10 years are listed in the table below.

Reports of drug-induced amnesia*

Drug

No. of reports

Percentage of total reports for drug

sertraline

19

0.9

Simvastatin

14

0.8

paroxetine

8

0.8

midazolam

5

2.1

dosulepin (dothiepin)

5

1.6

moclobemide

5

1.0

fluoxetine

5

0.5

ranitidine

5

0.4

*The drug with the highest proportion of reports (7:3.4%), dexfenfluramine, has recently been withdrawn.

Of the 219 reports of drug-induced amnesia analysed, there was a single drug suspected in the majority (84%) of the reports. Ages of the patients ranged from 5 to 98 years (median 48) and the onset of the reaction varied from the day drug therapy was commenced (over 25%) to many years afterwards, with most occurring during the first week of therapy. The reaction occurred on rechallenge in 16 of the patients and most of the patients had recovered at the time the report was submitted.

Reference: Australian Adverse Drug Reactions Bulletin 17(3): 11 (1998).

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013